The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder

• Published in: Journal of psychopharmacology (Oxford) Vol. 24; no. 4; p. 537
• Main Authors: Boulton, D W, Balch, A H, Royzman, K, Patel, C G, Berman, R M, Mallikaarjun, S, Reeves, R A
• Format: Journal Article
• Language: English
• Published: United States 01.04.2010
• Subjects: Adult; Antidepressive Agents - blood; Antidepressive Agents - pharmacokinetics; Antipsychotic Agents - adverse effects; Antipsychotic Agents - pharmacokinetics; Antipsychotic Agents - therapeutic use; Aripiprazole; Citalopram - pharmacokinetics; Cyclohexanols - pharmacokinetics; Delayed-Action Preparations; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - metabolism; Double-Blind Method; Drug Interactions; Female; Fluoxetine - pharmacokinetics; Humans; Male; Middle Aged; Piperazines - adverse effects; Piperazines - pharmacokinetics; Piperazines - therapeutic use; Quinolones - adverse effects; Quinolones - pharmacokinetics; Quinolones - therapeutic use; Sertraline - pharmacokinetics; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult; United States

Possible effects of the atypical antipsychotic aripiprazole on the pharmacokinetics of standard antidepressant therapies (ADTs) were assessed in two open-label, non-randomised studies in healthy subjects (Studies 1 and 2) and two placebo-controlled studies in patients with major depressive disorder...